Acromegaly Epidemiology Forecast till 2030

DelveInsight Business Research LLP

Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.

Acromegaly Epidemiology Insights

• The total prevalent cases of Acromegaly in 2017 was 64,508
• The diagnosed patient pool cases in 2017 was 49,814 
• The prevalent population of Acromegaly in the United States in 2017 was 28,671  

• The prevalent cases of Acromegaly in Japan in 2017 was 10,690

• EU5 countries occupied around 38.98% of the patient pool amongst 7MM in 2017

• The diagnosed cases of Acromegaly based on types of Adenomas in the US in 2017:
  • 18,349 – Macroadenomas
  • 4,587 – Microadenomas

Acromegaly Epidemiology Segmentation in 7MM from 2017 to 2030

• Total Prevalent Cases of Acromegaly
• Diagnosed Cases of Acromegaly
• Origin Specific Diagnosed Prevalent Cases of Acromegaly
• Diagnosed Cases of Acromegaly Based on Types of Adenomas

Request for sample pages

Scope of the Report

• The Acromegaly report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Acromegaly Epidemiology Report and Model provide an overview of the risk factors and global trends of Acromegaly in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Acromegaly in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Acromegaly
• The report provides the segmentation of the Acromegaly epidemiology

Table of contents

1. Key Insights 

2. Executive Summary of Acromegaly

3. Acromegaly: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Acromegaly Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Acromegaly Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Acromegaly Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Acromegaly Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Acromegaly Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Acromegaly Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Acromegaly Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Acromegaly Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Acromegaly Treatment and Management

6.2. Acromegaly Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/